About the Authors
- Alastair J. King
-
Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America
- Marc R. Arnone
-
Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America
- Maureen R. Bleam
-
Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America
- Katherine G. Moss
-
Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America
- Jingsong Yang
-
Affiliation GlaxoSmithKline Department of Enzymology & Mechanistic Pharmacology, Collegeville, Pennsylvania, United States of America
- Kelly E. Fedorowicz
-
Affiliation GlaxoSmithKline Department of Enzymology & Mechanistic Pharmacology, Collegeville, Pennsylvania, United States of America
- Kimberly N. Smitheman
-
Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America
- Joseph A. Erhardt
-
Current address: Janssen Oncology R&D, Radnor, Pennsylvania, United States of America
Affiliation GlaxoSmithKline Portfolio Management, Collegeville, Pennsylvania, United States of America
- Angela Hughes-Earle
-
Affiliation GlaxoSmithKline Department of Safety Assessment, King of Prussia, Pennsylvania, United States of America
- Laurie S. Kane-Carson
-
Affiliation GlaxoSmithKline Department of Screening & Compound Profiling, GlaxoSmithKline, Durham, North Carolina, United States of America
- Robert H. Sinnamon
-
Affiliation GlaxoSmithKline Department of Biological Reagents & Assay Development, King of Prussia, Pennsylvania, United States of America
- Hongwei Qi
-
Affiliation GlaxoSmithKline Department of Biological Reagents & Assay Development, King of Prussia, Pennsylvania, United States of America
- Tara R. Rheault
-
Affiliation GlaxoSmithKline Department of Medicinal Chemistry, GlaxoSmithKline, Durham, North Carolina, United States of America
- David E. Uehling
-
Current address: Ontario Institute for Cancer Research, MaRS Centre, Toronto, Ontario, Canada
Affiliation GlaxoSmithKline Department of Medicinal Chemistry, GlaxoSmithKline, Durham, North Carolina, United States of America
- Sylvie G. Laquerre
-
* E-mail: sylvie.g.laquerre@gsk.com
Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America
Competing Interests
The authors are specifying that at the time the research was performed, all authors were GlaxoSmithKline (GSK) employees and received compensation from GSK. GSK also funded the research and financed patent applications linked to the discoveries described in the manuscript. GSK intends to commercialize dabrafenib, pending approval. GSK will adhere to all the PLOS ONE policies on sharing data and materials for non-human research purposes.
Author Contributions
Conceived and designed the experiments: AJK MRA MRB JY JAE SGL TRR DEU. Performed the experiments: MRA MRB KGM JY KEF KNS AHE LSKC RHS HQ. Analyzed the data: AJK AHE SGL. Contributed reagents/materials/analysis tools: TRR DEU. Wrote the paper: AJK SGL.